Improving Outcomes in NSCLC: Treatment and Prognostication Updates

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Improving Outcomes in NSCLC: Treatment and Prognostication Updates

By Maen Hussein 3 Videos

0 views

February 23, 2024

On March 1, 2024, The FDA has approved amivantamab-vmjw (RYBREVANT®) plus carboplatin and pemetrexed for ...
read more ↘ the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
↖ read less

Comments 0